$DK

Our AI knew it: Up 13% premarket, this energy stock is now up +57% By Investing.com

Investing.com’s InvestingPro AI picks highlight gains after US markets reopened. Delek US Energy (NYSE:DK) rose about 12.7% premarket after a TD Cowen upgrade; the article cites potential value of small refinery exemptions up to $18/share. It also notes Molina Healthcare (NYSE:MOH) up ~69% after a Medicaid contract covering 3M beneficiaries starting Jan. 1, 2027.

Original reporting
Published Jul 6, 2026, 8:23 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 6, 2026, 8:45 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefMarket movers
Primary signal
$DK
Bullish
medium confidence
Mentioned
$DK · $MOH
Relevance
6/10
alphai data visualization · based on investing.com
Decision brief

The 30-second read

$DKBullishMed
01

Why it matters

The only same-day, attributable catalyst described is DK’s TD Cowen upgrade driving premarket strength; MOH’s Medicaid contract is a fundamental tailwind but presented as part of longer-running performance since the AI pick.

02

Market read

Traders can act on DK’s upgrade-driven premarket momentum; MOH’s contract supports a longer-horizon valuation/re-rating narrative but is not clearly a fresh disclosure in this article.

03

What to watch

Analyst-upgrade catalysts can reverse quickly; for MOH, reimbursement rate details and execution risk of cost management could matter more than contract headline duration.

Relevance 6/10Novelty 5/10Timing: Premarket today after the TD Cowen upgrade catalyst for DK.

Background

The piece is a promotional “AI stock picks” roundup that also cites specific catalysts: a TD Cowen upgrade for Delek and a Medicaid contract for Molina.

Company-level read

Ticker impact

$DKBullishMedium confidence
Context

Delek US Energy is surging in premarket after a TD Cowen upgrade, citing small refinery exemption value and durability.

Expected impact

Likely continued upside pressure at the open, with volatility elevated given premarket strength and upgrade-driven positioning.

Evidence & confidence

The article attributes the same-day move to a specific analyst upgrade and provides a concrete exemption-value framework, but it’s still an analyst-driven catalyst rather than a new company filing/print.

$MOHBullishMedium confidence
Context

Molina Healthcare is up since its AI pick after locking in a new Medicaid contract covering 3M+ beneficiaries starting Jan. 1, 2027.

Expected impact

Moderate positive bias over coming weeks as investors digest contract economics and duration.

Evidence & confidence

The contract details (beneficiary count, start date, term/option) are specific, but the article frames the move as follow-through since the pick rather than a newly disclosed contract today.

Market effects

Energy and healthcare names are highlighted as benefiting from policy/contract tailwinds (biofuel exemptions; Medicaid contracting), potentially reinforcing sector momentum.

US-focused catalysts (US biofuel mandates; US Medicaid contract) with read-across to domestic managed-care and refining sentiment.

Limited direct global linkage; mostly US policy-driven fundamentals.

Counterpoint

DK’s move may fade if the market already priced exemption value or if exemption durability is questioned; MOH’s contract may be known to the market and priced into momentum.

Key entities

  • Delek US Energy

    Energy stock upgraded by TD Cowen; article links the upgrade to small refinery exemption value and a structural cost advantage.

  • Molina Healthcare

    Managed-care company that locked in a Medicaid contract covering 3M+ beneficiaries with a multi-year term starting Jan. 1, 2027.

  • TD Cowen (Jason Gabelman)

    Named as the source of the DK upgrade and the exemption-value thesis.

Related articles

$DKMedAI 8/10

Delek US Holdings (DK) Q2 2026 Earnings Call Transcript

Delek US Holdings (DK) reported Q2 2026 net income of $170 million ($2.71/share) and adjusted net income of $344 million ($5.48/share). Adjusted EBITDA was $639 million, with RVO-adjusted EBITDA of $490 million and RVO-adjusted EPS of $3.64. Logistics segment adjusted EBITDA was a record $144 million. DKL full-year 2026 EBITDA guidance is $520 million to $560 million.

$DKMed

Delek Slides on Q2 Results

Delek US Holdings (NYSE: DK) reported Q2 ended June 30, 2026 net income of $169.5M ($2.71/share) and adjusted net income of $343.9M ($5.48/share). Adjusted EBITDA was $638.7M; excluding RVO impacts, adjusted EPS was $3.64 and adjusted EBITDA $490.1M. Delek Logistics posted adjusted EBITDA of $143.5M and is targeting $520-560M. Delek bought $20M of DK shares and paid $15.6M in dividends, declaring a $0.255 quarterly dividend.

$MOHMedAI 8/10

Molina Healthcare Q2 Earnings Call Highlights

Molina Healthcare (MOH) discussed Q2 results on its earnings call. Medicaid MCR was 92.4% in first half, expected to rise to 93.3% in second half. Medicare MCR was 90.7% and full-year Medicare MCR guidance was cut to 92.2%, with 2026 EPS contribution of $0.25. Marketplace MCR pressure led to raised 2026 guidance to 90% and a shift to a $0.75 per share loss. 2027 premium outlook is about $46.5B.

$MOHMedAI 8/10

Molina Healthcare Posts Lower Q2 Earnings, Raises Full-Year Guidance; Stock Down

Molina Healthcare (MOH) reported Q2 2026 revenue of $10.87B, down 5% from Q2 2025, with GAAP net income falling to $60M ($1.19/share) from $255M ($4.75). Adjusted net income was $77M ($1.51). Medical care ratio rose to 92.2%. Despite weaker results, the company raised full-year guidance for GAAP earnings to at least $2.15/share and adjusted to at least $5.25/share.

$MOHMedAI 8/10

Why is Molina Healthcare stock sliding today? By Investing.com

Molina Healthcare (MOH) fell about 9.2% in pre-open trading after reporting Q2 2026 results. Adjusted EPS was $1.51 vs. ~$1.39–$1.40 expected, and revenue was ~$10.87B. Full-year 2026 revenue guidance was ~$42B vs. ~$44.28B consensus, with Medicaid margin “trough year” comments, enrollment pressure, and Florida CMS contract startup costs cited.

$MOHMedAI 8/10

Molina raises full year 2026 guidance after Q2 results

Molina Healthcare reported Q2 2026 adjusted EPS of $1.51, above the $1.39 consensus. Revenue fell to $10.874B from $11.427B a year earlier, while GAAP net income declined to $60M. The company raised full-year 2026 adjusted guidance to at least $5.25 per diluted share and GAAP to at least $2.15. Analysts at RBC, Wells Fargo, and TD Cowen raised price targets for MOH.